新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 强生 » 欧盟分别批准强生和Celgene白血病新药

欧盟分别批准强生和Celgene白血病新药

来源:生物谷 2013-08-12 20:28

2013年8月12日讯 /生物谷BIOON/ --欧盟委员会上周通过了强生公司的Velcade和Celgene公司的Imnovid。这两种药物都是用于治疗多发性骨髓瘤。其中强生公司的Velcade已经被用于一些临床病例,这次批准将有助于两种新药扩大其市场份额。(生物谷Bioon.com)

详细英文报道:

The European Commission was good to blood cancer drugmakers this week, granting multiple myeloma approvals for Johnson & Johnson's ($JNJ) Velcade and Celgene's ($CELG) Imnovid. While Velcade was already approved for certain multiple myeloma cases, the new guidance will open up its market to cover earlier use in the cancer. Velcade, in combination with certain other drugs, can now be used as a first-line treatment option for adults. Velcade is one of the drugs that J&J has been pushing for line extensions to boost revenue while it builds out products in its pipeline. Imnovid's approval is more limited in scope: It covers use of the drug in adult patients who have received at least two prior therapies and still demonstrated disease progression.

 

本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库